Glutamine-Derived 2-Hydroxyglutarate Is Associated with Disease Progression in Plasma Cell Malignancies
Gonsalves, W.I.; Ramakrishnan, V.; Hitosugi, T.; et al.
To better understand the clinical significance of 2-hydroxyglutarate (2-HG) in its progression of plasma cell malignancies, Gonsalves and colleagues investigated the production and flux of TCA cycle metabolites in various cell and tissue analyses. The quantitative assessments were facilitated by a stable isotope-resolved metabolomics (SIRM) approach that utilized U-13C standards and MS-based methodologies. This study revealed that 2-HG is produced from clonal plasma cells (PCs) and is detectable in the peripheral blood and bone marrow plasma of patients with PC disorders. Also observed was evidence for the exclusive production of 2-HG from glutamine metabolism that appears to be correlated with c-Myc upregulation. This is a clinically significant finding considering the functional link of 2-HG with multiple myeloma that has the potential to be exploited as a decision factor in therapy initiation.
Articles
- Lysine Propionylation Boosts Proteome Sequence Coverage and Enables a “Silent SILAC” Labeling Strategy for Relative Protein Quantification
- 13C-Labeled Yeast as Internal Standard for LC-MS/MS and LC High Resolution MS Based Amino Acid Quantification in Human Plasma
- Glutamine-Derived 2-Hydroxyglutarate Is Associated with Disease Progression in Plasma Cell Malignancies
- Hepatic Ketogenic Insufficiency Reprograms Hepatic Glycogen Metabolism and the Lipidome
- A Targeted Metabolomics Approach for Clinical Diagnosis of Inborn Errors of Metabolism
- A Guide to 13C Metabolic Flux Analysis for the Cancer Biologist
- SNMMI Image of the Year Is the Endocyte 177 Lu PSMA-617?
